Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 6/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | PRKCG | P05129 | 1/20 | 0.47 |
| ▸ | PRKCB | P05771 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | PRKCH | P24723 | 1/20 | 0.47 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.47 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.47 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL902734 | 1.00 | DNM1 (0.50) | DNM1PRKD3PRKCGPRKCBPRKCA | |
| Hydrochloric Acid SCHEMBL8848726 | 0.98 | DNM1 (0.52) | DNM1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL9129474 | 0.93 | PRKD3 (0.56) | DNM1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL9129466 | 0.93 | PRKD3 (0.56) | DNM1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL8080961 | 0.88 | LPAR1 (0.55) | — | |
| SCHEMBL8855809 | 0.88 | DNM1 (0.64) | DNM1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL8855808 | 0.88 | DNM1 (0.64) | DNM1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL8855785 | 0.88 | DNM1 (0.64) | DNM1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL30966867 | 0.88 | LPAR1 (0.55) | — | |
| SCHEMBL8855743 | 0.88 | DNM1 (0.64) | DNM1PRKD3PRKCGPRKCBPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192783-A1 | RECOMBINANT POLYPEPTIDES FOR MEMBRANE FUSION AND USES THEREOF | Innovascreen Inc. (CA) | 2023-06-22 | — | — | US | disclosed |
| WO-2012040825-A1 | RECOMBINANT POLYPEPTIDES FOR MEMBRANE FUSION AND USES THEREOF | Innovascreen Inc. (CA) | 2012-04-05 | — | — | WO | disclosed |
| EP-1824978-A4 | HCV F PROTEIN AND USES THEREOF | VALORISATION HSJ SOC EN COMMAN (CA) | 2008-09-10 | — | — | EP | disclosed |
| EP-1220925-B8 | CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF | SANOFI PASTEUR LTD (CA) | 2008-04-23 | — | — | EP | disclosed |
| WO-2006053439-A9 | HCV F PROTEIN AND USES THEREOF | VALORISATION HSJ SOC EN COMMAN (CA) | 2008-02-21 | — | — | WO | disclosed |
| EP-1824978-A1 | HCV F PROTEIN AND USES THEREOF | Valorisation HSJ, Societe en Commandite (CA) | 2007-08-29 | — | — | EP | disclosed |
| WO-2002018595-A9 | MORAXELLA POLYPEPTIDES AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF | AVENTIS PASTEUR (CA) | 2007-08-23 | — | — | WO | disclosed |
| WO-2006053439-A1 | HCV F PROTEIN AND USES THEREOF | VALORISATION HSJ, SOCIETE EN COMMANDITE (CA) | 2006-05-26 | — | — | WO | disclosed |
| US-20060088542-A1 | Imidazoquinoline adjuvants for vaccines | POWDERMED LIMITED | 2006-04-27 | — | — | US | disclosed |
| WO-2002016440-A9 | HAEMOPHILUS INFLUENZAE LIPOPOLYSACCHARIDE INNER-CORE OLIGOSACCHARIDE EPITOPES AS VACCINES FOR THE PREVENTION OF HAEMOPHILUS INFLUENZAE INFECTIONS | AVENTIS PASTEUR (CA) | 2004-05-13 | — | — | WO | disclosed |
| WO-2000032794-A2 | CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF | AVENTIS PASTEUR LIMITED (CA) | 2000-06-08 | — | — | WO | disclosed |
| WO-2000024765-A2 | CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF | AVENTIS PASTEUR LIMITED (CA) | 2000-05-04 | — | — | WO | disclosed |
| WO-2000011013-A1 | MODIFIED NUCLEOMONOMERS AND METHODS OF USE THEREOF | UNIVERSITY OF NEBRASKA BOARD OF REGENTS (US) | 2000-03-02 | — | — | WO | disclosed |
| US-5969135-A | COMPOUNDS FOR USE AS ANTISENSE CONTROL OF GENE EXPRESSION AND HYBRIDIZATION | ICN PHARMACEUTICALS, INC. (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0789706-A4 | SUGAR MODIFIED NUCLEOSIDES AND THEIR USE FOR SYNTHESIS OF OLIGONUCLEOTIDES | ICN PHARMACEUTICALS (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0789707-A4 | AMINO ACID NUCLEIC ACIDS | ICN PHARMACEUTICALS (US) | 1999-02-24 | — | — | EP | disclosed |
| EP-0789707-A1 | AMINO ACID NUCLEIC ACIDS | ICN PHARMACEUTICALS (US) | 1997-08-20 | — | — | EP | disclosed |
| EP-0789706-A1 | SUGAR MODIFIED NUCLEOSIDES AND THEIR USE FOR SYNTHESIS OF OLIGONUCLEOTIDES | ICN PHARMACEUTICALS (US) | 1997-08-20 | — | — | EP | disclosed |
| WO-1996014329-A1 | SUGAR MODIFIED NUCLEOSIDES AND THEIR USE FOR SYNTHESIS OF OLIGONUCLEOTIDES | ICN PHARMACEUTICALS (US) | 1996-05-17 | — | — | WO | disclosed |
| WO-1996014330-A1 | AMINO ACID NUCLEIC ACIDS | ICNPHARMACEUTICALS (US) | 1996-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060088542-A1 | Imidazoquinoline adjuvants for vaccines | IRF3, TLR7, STING1 | DNM1 2617/4885PRKD3 2312/4885PRKCG 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.